← Back to Search

Stem Cell Transplantation

Haploidentical Stem Cell Transplantation for Blood Cancers

N/A
Waitlist Available
Led By Brian Shaffer, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial will test if using half-matched donors with favorable KIR genes can reduce the risk of cancer returning after a transplant.

Eligible Conditions
  • Blood Cancers

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
proportion of patients undergoing an allo HCT transplant who have a KIR favorable donor.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients will undergo donor/recipient bone marrowExperimental Treatment8 Interventions
All patients will undergo haploidentical, allogeneic hematopoietic cell transplantation. Conditioning will consist of fludarabine, melphalan, and thiotepa. Graft versus host disease prophylaxis will be with post-transplant cyclophosphamide in addition to standard tacrolimus and mycophenolate mofetil. Donors will undergo HLA and KIR geno- and allotyping to determine the best donor.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Filgrastim
2000
Completed Phase 3
~3670
Tacrolimus
2011
Completed Phase 4
~4740
Mycophenolate Mofetil
1997
Completed Phase 4
~2380
Mesna
2003
Completed Phase 2
~1380
Cyclophosphamide
1995
Completed Phase 3
~3780
melphalan
1994
Completed Phase 3
~3530
fludarabine
2012
Completed Phase 3
~6760
thiotepa
2005
Completed Phase 3
~1310

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,933 Previous Clinical Trials
585,576 Total Patients Enrolled
1 Trials studying Blood Cancers
25 Patients Enrolled for Blood Cancers
Brian Shaffer, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
2 Previous Clinical Trials
13 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants have been enlisted in this research endeavor?

"This medical investigation is no longer acceping enrollees. It was originally posted on August 23rd 2016 and recently updated on January 21st 2022. If you are searching for alternative trials, there are 263 studies involving malignancies that are still recruiting participants, as well as 1126 investigations surrounding the efficacy of tacrolimus."

Answered by AI

Have any prior investigations been conducted in regards to Tacrolimus?

"Presently, there are 1126 clinical trials that employ Tacrolimus as part of the study. Of these studies, 209 have been approved to enter Phase 3, and they span 32830 sites across Leipzig, Sachsen."

Answered by AI

Am I eligible to participate in this research experiment?

"This clinical trial seeks to recruit 44 participants with malignant haematological disorders, aged between 18 and 75. To be eligible for the study, patients must have t(9;22) or confirmed BCR-ABL1 translocation by genomic testing, mutations of IKZF1 or CRLF2 genes, 11q23 (MLL)-related alterations, hypodiploid karyotype, deletion of 9p chromosome region, loss of 17p locus or TP53 mutation as well as T-lymphocyte lineage antigen expression in acute lymphoblastic leukemia cases with CNS involvement or other extramed"

Answered by AI

Is recruitment presently open for this clinical research endeavor?

"The clinical trial, initially posted on August 23rd 2016 and last modified on January 21st 2022, is no longer recruiting. Nevertheless, 1389 other studies are currently seeking participants."

Answered by AI

What health conditions can Tacrolimus be employed to alleviate?

"Tacrolimus is commonly prescribed for dermatitis, atopic and other conditions like psoriasis, multiple sclerosis, acute myelocytic leukemia."

Answered by AI

Is the study open to seniors aged sixty and above?

"As per the prerequisites for this medical trial, potential participants must be no younger than 18 and not exceed 75 years of age."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
2016. "Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02880293.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top